Drugs / RNS60
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02525471 | Oct 2015 → Jun 2017 | amyotrophic lateral sclerosis | Sabrina Paganoni, M.D. | Completed | No outcome recorded |
| Phase 1 | NCT02490865 | Jul → Aug 2015 | — | Revalesio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01511302 | Jun 2012 → Apr 2013 | asthma | Revalesio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01264783 | Jul → Sep 2011 | myocardial infarction | Revalesio Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01057498 | May → Nov 2010 | asthma | Revalesio Corporation | Completed | No outcome recorded |
| Phase 27 trials | ||||||
| Phase 2 | NCT02988297 | Oct 2026 → Nov 2028 | amyotrophic lateral sclerosis | Revalesio Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT04693715 | Jul 2021 → Nov 2023 | ischemic stroke | Revalesio Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02422121 | Apr → Nov 2015 | asthma | Revalesio Corporation | Completed | No outcome recorded |
| Phase 2 | NCT02497222 | ? → Jun 2016 | asthma | Revalesio Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT02005523 | ? → Oct 2014 | — | Revalesio Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT01714089 | — | relapsing-remitting multiple sclerosis | Revalesio Corporation | Withdrawn | No outcome recorded |
| Phase 2 | NCT01922427 | ? → Oct 2014 | — | Revalesio Corporation | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03456882 Comparator | May 2017 → Nov 2020 | amyotrophic lateral sclerosis | Mario Negri Institute for Pharmacological Research | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNS60 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02988297 ↗ |
| Modality | Other / unclassified | “RNS60 is a proprietary combination of oxygen supersaturated in saline” PMID 40671649 ↗ Jul 2025 |
| Route | Other | “RNS60, 4ml nebulized twice daily for 15 minutes.” NCT01057498 ↗ |